Treating-to-Target Post Methotrexate: New Treatment Horizons in RA from the 2017 ACR/ARHP Annual Meeting
This CME/CE-accredited CME Snapshot™ series of educational videos has been created for rheumatologists and other clinicians involved in treating patients with rheumatoid arthritis (RA). During each 15-minute activity, two expert rheumatologists focus on a specific aspect of long-term RA management, including practical advice on implementing international treat-to-target guidelines as well as the mechanistic profiles and clinical evidence for therapies designed to inhibit signaling via interleukin-6 (IL-6) or members of the Janus kinase (JAK) family of enzymes. Some of the modules also include 3D-animated elements to illustrate the relationships between the heterogeneous pathophysiologic mechanisms underlying RA and certain targeted biologic or synthetic disease-modifying treatment options.
This activity has been designed to meet the educational needs of rheumatologists and other clinicians involved in the ongoing management of patients with RA.
Learning Outcome Statements:
At the conclusion of this activity:
- KNOWLEDGE: Participants will self-report knowledge gained based on current best practices when treating patients with rheumatoid arthritis (RA).
- COMPETENCE/SKILL: Participants will self-report intent to change practice by applying current best practices when treating patients with rheumatoid arthritis (RA).
Upon completion of this activity, participants will be better able to do the following:
- Discuss the clinical profiles and published evidence for current and emerging targeted inhibitors of key proinflammatory factors involved in RA pathogenesis
- Tailor treatment regimens based on ongoing disease activity and other manifestations, therapeutic responses, and current recommendations for biologic and targeted synthetic DMARDs
Leonard H. Calabrese, DO
John R. P. Tesser, MD
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Name of Faculty or Presenter|
Relationship Identified With:
Leonard H. Calabrese, DO
Consultant/Advisor: AbbVie Inc.; Crescendo Bioscience, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Horizon Pharma plc; Janssen Pharmaceuticals, Inc.; Medimmune, LLC; Pfizer Inc.; UCB, Inc.
Speakers’ Bureau: AbbVie Inc.; Crescendo Bioscience, Inc.; Genentech, Inc.; Horizon Pharma plc; Janssen Pharmaceuticals, Inc.; Medimmune, LLC; UCB, Inc.
John R. P. Tesser, MD
Consultant/Advisor: Eli Lilly and Company; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi-Genzyme
Speakers’ Bureau: AbbVie Inc., Eli Lilly and Company; Genentech, Inc.; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi-Genzyme
Research Grant: AbbVie Inc., Eli Lilly and Company; Genentech, Inc.; Gilead Sciences, Inc.; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi-Genzyme
Employment (spouse): Regeneron Pharmaceuticals, Inc.
Non-faculty: Rose O’Connor, PhD; Jim Kappler, PhD; Sandy Breslow; Alison Kemp; Marilu Kelly, MSN, RN, CNE; and Bernard M. Abrams, MD, hereby state that neither they nor their spouses/life partners have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
This activity has been supported by independent educational grants from Gilead Sciences, Inc., and Sanofi Genzyme and Regeneron Pharmaceuticals.
Jointly provided by the Elsevier Office of Continuing Medical Education, Elsevier, and Integritas Communications.
CME Credit (Physicians)
The Elsevier Office of Continuing Medical Education (EOCME) is accredited by the ACCME to provide continuing medical education for physicians.
The EOCME designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credits commensurate with the extent of their participation in the activity.
CNE CREDIT (NURSES)
This continuing nursing education activity, provided by Elsevier, awards 0.25 contact hours for nurses. Elsevier is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of EOCME, Elsevier, and Integritas Communications.
CME Inquiries/Special Needs
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
For all CNE inquiries or special needs, please contact email@example.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Elsevier, Integritas Communications, Gilead Sciences, Inc., and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 0.25 AMA PRA Category 1 Credit(s)™
- 0.25 Nursing Contact Hours
- 0.25 Non-physician